Sepmag

Executive Summary

Sepmag is a Spanish biotechnology company specializing in advanced magnetic bead separation systems for diagnostic and bioprocessing applications. Founded in 2004 and headquartered in Barcelona, the company has developed a proprietary technology that delivers uniform magnetic force and real-time optical monitoring, enabling precise, reproducible, and scalable separation of biological targets such as nucleic acids, cells, proteins, and antibodies. Serving research laboratories, diagnostic developers, and industrial bioprocessors, Sepmag's systems are designed to bridge the gap from academic research to large-scale manufacturing, offering a reliable alternative to traditional separation methods. With over two decades of operational history and a focus on automation and quality, Sepmag is well positioned to capitalize on the growing demand for efficient bioproduction and point-of-care diagnostics. The company's technology is applicable across multiple market segments, including molecular diagnostics, cell therapy, and antibody purification. While Sepmag remains privately held and has not disclosed fundraising details, its established presence and continuous innovation suggest a solid foundation for future growth. Key opportunities include expanding its product portfolio, securing partnerships with larger diagnostic firms, and entering new geographic markets.

Upcoming Catalysts (preview)

• Q3 2026Launch of next-generation automated magnetic separation platform70% success
• TBDStrategic partnership with a global diagnostics company50% success
• TBDExpansion into North American or Asian markets60% success